174 related articles for article (PubMed ID: 21654386)
21. The role of topoisomerase-I inhibitors in the treatment of non-Hodgkin's lymphoma.
Cabanillas F
Semin Hematol; 1999 Oct; 36(4 Suppl 8):11-5. PubMed ID: 10622224
[TBL] [Abstract][Full Text] [Related]
22. New drugs for the treatment of non-Hodgkin lymphomas.
Smith SM
Chin Clin Oncol; 2015 Mar; 4(1):14. PubMed ID: 25841721
[TBL] [Abstract][Full Text] [Related]
23. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma.
Witzig TE; Wiernik PH; Moore T; Reeder C; Cole C; Justice G; Kaplan H; Voralia M; Pietronigro D; Takeshita K; Ervin-Haynes A; Zeldis JB; Vose JM
J Clin Oncol; 2009 Nov; 27(32):5404-9. PubMed ID: 19805688
[TBL] [Abstract][Full Text] [Related]
24. Next Generation of Targeted Molecules for Non-Hodgkin Lymphomas: Small-Molecule Inhibitors of Intracellular Targets and Signaling Pathways.
Choe H; Ruan J
Oncology (Williston Park); 2016 Sep; 30(9):847-58. PubMed ID: 27633417
[TBL] [Abstract][Full Text] [Related]
25. Rituximab-mediated chemosensitization of AIDS and non-AIDS non-Hodgkin's lymphoma.
Bonavida B; Vega MI
Drug Resist Updat; 2005; 8(1-2):27-41. PubMed ID: 15939340
[TBL] [Abstract][Full Text] [Related]
26. Bortezomib sensitizes non-Hodgkin's lymphoma cells to apoptosis induced by antibodies to tumor necrosis factor related apoptosis-inducing ligand (TRAIL) receptors TRAIL-R1 and TRAIL-R2.
Smith MR; Jin F; Joshi I
Clin Cancer Res; 2007 Sep; 13(18 Pt 2):5528s-5534s. PubMed ID: 17875785
[TBL] [Abstract][Full Text] [Related]
27. Current treatment of follicular and low-grade non-Hodgkin's lymphoma.
Linch D
Anticancer Drugs; 2001 Jun; 12 Suppl 2():S5-9. PubMed ID: 11508934
[TBL] [Abstract][Full Text] [Related]
28. Malignant non-Hodgkin's lymphoma of childhood and adolescence in Austria--therapy results between 1986 and 2000.
Attarbaschi A; Mann G; Dworzak M; Trebo M; Urban C; Fink FM; Horcher E; Reiter A; Riehm H; Gadner H;
Wien Klin Wochenschr; 2002 Dec; 114(23-24):978-86. PubMed ID: 12635465
[TBL] [Abstract][Full Text] [Related]
29. [Efficacy of GDP regimen (gemcitabine, dexamethasone, and cisplatin) on relapsed or refractory aggressive non-Hodgkin's Lymphoma: a report of 24 cases].
Fan Y; Huang ZY; Luo LH; Yu HF
Ai Zheng; 2008 Nov; 27(11):1222-5. PubMed ID: 19000458
[TBL] [Abstract][Full Text] [Related]
30. [Efficacy of alternating triple therapy on relapsed or refractory non-Hodgkin's lymphoma].
Tian H; Chen J; Wu Y; Li LL
Ai Zheng; 2008 Jun; 27(6):633-5. PubMed ID: 18570739
[TBL] [Abstract][Full Text] [Related]
31. Molecular neuro-oncology and the development of targeted therapeutic strategies for brain tumors. Part 5: apoptosis and cell cycle.
Newton HB
Expert Rev Anticancer Ther; 2005 Apr; 5(2):355-78. PubMed ID: 15877531
[TBL] [Abstract][Full Text] [Related]
32. [Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma].
Zhou SY; Shi YK; He XH; Zhang P; Dong M; Huang DZ; Yang JL; Zhang CG; Liu P; Yang S; Feng FY
Ai Zheng; 2005 Apr; 24(4):465-9. PubMed ID: 15820071
[TBL] [Abstract][Full Text] [Related]
33. B-cell receptor pathway modulators in NHL.
Blum KA
Hematology Am Soc Hematol Educ Program; 2015; 2015():82-91. PubMed ID: 26637705
[TBL] [Abstract][Full Text] [Related]
34. Pathogenesis of non-Hodgkin's lymphoma.
Nogai H; Dörken B; Lenz G
J Clin Oncol; 2011 May; 29(14):1803-11. PubMed ID: 21483013
[TBL] [Abstract][Full Text] [Related]
35. Rituximab therapy for indolent non-Hodgkin's lymphoma.
Hagenbeek A; Czuczman MS; Ghielmini M; Herold M; Kimby E; Solal-Céligny P; Unterhalt M
Anticancer Drugs; 2002 Nov; 13 Suppl 2():S11-7. PubMed ID: 12710586
[TBL] [Abstract][Full Text] [Related]
36. [Recent progress in the treatment of malignant lymphoma].
Ogura M
Gan To Kagaku Ryoho; 2001 Sep; 28(9):1213-35. PubMed ID: 11579632
[TBL] [Abstract][Full Text] [Related]
37. Targeting histones and proteasomes: new strategies for the treatment of lymphoma.
O'Connor OA
J Clin Oncol; 2005 Sep; 23(26):6429-36. PubMed ID: 16155030
[TBL] [Abstract][Full Text] [Related]
38. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
Wiernik PH; Lossos IS; Tuscano JM; Justice G; Vose JM; Cole CE; Lam W; McBride K; Wride K; Pietronigro D; Takeshita K; Ervin-Haynes A; Zeldis JB; Habermann TM
J Clin Oncol; 2008 Oct; 26(30):4952-7. PubMed ID: 18606983
[TBL] [Abstract][Full Text] [Related]
39. The role of high-dose chemotherapy in patients with Hodgkin's disease and non-Hodgkin's lymphoma.
Laport GF; Williams SF
Semin Oncol; 1998 Aug; 25(4):503-17. PubMed ID: 9728600
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis.
Alas S; Emmanouilides C; Bonavida B
Clin Cancer Res; 2001 Mar; 7(3):709-23. PubMed ID: 11297268
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
